ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2025
Breast Cancer Polygenic Risk Score Associated with Outcomes after In Situ Breast Disease.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundDuctal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS) are preinvasive breast lesions. DCIS is treated more aggressively, as it is more likely to develop into invasive disease than LCIS. Both DCIS and LCIS face an elevated risk of contralateral breast cancer. It is thus important to identify those at high risk of further breast disease in order to personalize treatment.
methodsThis study evaluated whether the 313-SNP breast cancer polygenic risk score (PRS313) can predict the likelihood of developing ipsilateral or contralateral breast cancer after diagnosis of DCIS or LCIS by analyzing data from patients diagnosed with DCIS (N = 2,169) or LCIS (N = 185) from the Investigate the genetiCs of In situ Carcinoma of the ductaL subtypE (ICICLE) and A study to investigate the Genetics of LobulAr Carcinoma In situ in EuRope (GLACIER) studies, with a median follow-up of 11 years. Outcomes included any further in situ or invasive breast disease (including distant metastasis), ipsilateral breast disease, invasive ipsilateral breast disease, and contralateral breast disease.
resultsCox regression analysis revealed a significant association between increasing continuous PRS313 and the risk of contralateral disease following DCIS (HR = 1.30; 95% confidence interval, 1.08-1.56) and a link between PRS313 and ipsilateral disease after LCIS (HR = 2.16; 95% confidence interval, 1.22-3.81).
conclusionsThis research provides strong evidence that PRS313 can serve as a valuable predictor of future breast cancer events in women with in situ breast cancer, specifically contralateral disease after DCIS and ipsilateral disease after LCIS. IMPACT: PRS313 has the potential to guide clinical decisions about surveillance, risk-reduction treatments, and personalized care in those with in situ breast cancers, which could improve outcomes and optimize the use of healthcare resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.